genic variation of the virus. Neutralizing antibodies appear to act specifically against the haemagglutinins, particularly the distal region, which contains five antigenically important surface epitopes surrounding a conserved region that represents the receptor binding site. The main problem with vaccine development is that the important epitopes differ between virus variants and humoral cross-immunity is poor. There is some hope that peptides based on better conserved areas of haemagglutinins may be able to produce good cellular immune response.
The importance of immune stimulation of mucosal surfaces was outlined by Professor F J Bourne (Bristol Veterinary School) . Many pathogens enter the body via mucosae and systemic vaccination is often not protective for the diseases they cause. Mucosal vaccines mimic the pathogen entry route and are more effective. Also, oral vaccines are easier to administer in many food animal production regimens. Mucosally presented antigen can stimulate systemic humoral and cellular immunity as well as local immunity, and can also provide some protection for distant mucosal sites via the common mucosal system. Complex protection mechanisms depending largely on IgA and suppressor T-cells exist in the gut to prevent wasteful or harmful immune responses to dietaryantigens. Vaccine antigens need to be presented in a special way to avoid induction of tolerance. Previously, it was thought that all antigens processed by the gut immune system were sampled via the Peyer's patches. Recent studies have shown that the enterocyte can express class 2 MHC antigen and process and present foreign antigen to T-cells.
Professor E J L Soulsby (Cambridge Veterinary School) described factors in unresponsiveness to parasite vaccines. The measured immune response is often good, but parasites have evolved many mechanisms of evasion. Young animals often produce a poorer immune response than adults and so are most affected by such diseases. Pregnancy, parturition and lactation have all been shown to reduce the host immune response against gastrointestinal nematodes. In sheep, this allows the parasites to mature and results in an increased contamination of the pasture with-eggs, which subsequently affect the lambs. In addition, parasites in the gut of the ewe produce suppressor factors, which are transferred to the lamb via the colostrum. He postulated that these factors induce a suppressor T-cell population in the lamb, which makes vaccination ineffective, and which may persist until 14-16 weeks of age. Future research would concentrate on investigating the suppressor factors and on identifying helminth antigens which could be protective for the neonate.
Mr D Danson (Duphar Ltd) outlined the problems of getting a vaccine onto the veterinary market. The economic climate is of a stagnant agricultural market and increased competition, and scientific research is being carefully tailored to meet the veterinary and commercial needs of the customer. A range of vaccines exist or are in development, including live, inactivated, subunit, synthetic and anti-idiotype preparations. Each has to be evaluated on the grounds of efficacy, safety and cost. The new generation of recombinant DNA vaccines, such as deletion mutants and the live herpes and vaccinia recombinant carriers, are cheap and effective, but their safety is unknown. It might be better to concentrate on the development of subunit and synthetic vaccines rather Journal ofthe RoyalSocietyofMedicine Volume 80 September1987 595 than risk the release oflive engineered organisms into the environment.
Adjuvants were reviewed by Professor J H L Playfair (Middlesex Hospital Medical School). As potential vaccine antigens are getting smaller in molecular size and so have less immunogenicity, the need for effective adjuvants is increasing. Vehicles such as Iiposomes, iscoms and pluronic polyols, and physiological agents such as interleukin 1, gammainterferon and Ig M, have all been shown to have adjuvant properties, as well as the established depot, bacterial and bacterial derivatives. Side effects are an important consideration with adjuvants, such as granuloma formation with aluminium hydroxide and fever with gamma-interferon and interleukin l. Autoimmunity seems not to be a clinical problem even with good adjuvants. The mechanism of adjuvant activity is probably the increased expression of class 2 MHC antigens and increased interleukin 1 production, both of which have fundamental effects on antigen presentation and immune cell activation.
A wide range of topics was covered at the meeting and left no doubt that this, the oldest type of preventive medicine, has now become the site of new scientific ferment.
SSundaram

DHSS Department of Toxicology St Bartholomew's Hospital, London
CCIarke Bristol Veterinary School Acknowledgment: Our attendance at the meeting was supported by the generosity of Smith, Kline and French Research Ltd. This was attended by nearly 600 people, and was a masterly review of the post-receptor mechanisms involved in the action of peptide hormones, startling in its breadth of coverage. Professor Catt came armed with no less than 6 other seminars -a remarkable achievement. The greatest demand was for those on angiotensin and aldosterone, as well as those on the gonadotrophin-releasing hormones. He had detailed laboratory discussions with between 5 and 12 endocrine investigators each day, and all remarked on his perspicacity and helpfulness in discussing their research. Professor Catt proved to be indefatigable, despite what a distinguished British professor described as 'an itinerary for his destruction', and the educational value of his visits to young British researchers proved immense. Perhaps his only moments of peace and quiet were on a train, or when staying at the Domus Medica. He was, of course, entertained by the Clinical Endocrinology Trustees and also by the officers of the Section of Endocrinology.
The value of such visits, however, is not just oneway, and is well exemplified by Professor Catt's remark to me that he had not previously realized how well focused is British endocrine research, nor how diverse. British endocrinology and the Section of Endocrinology in particular express their gratitude to Professor Catt and the Trustees for making such a marvellous visit possible.
CWBurke
Honorary Secretary Section of Endocrinology
Forthcoming events
People on the Margins of Society: Strategies against Exclusion 14th WSW Regional Symposium, 20-25 September 1987in Rome Topics for discussion will include: forms and perceptions of social marginalization; circumstances under which it persists and its reproduction processes; public policies and strategies aimed at fighting it, including the efforts of voluntary organizations, volunteers and self-help groups. 
Letters to the Editor
Preference is given to letters commenting on contributions published recently in the JRSM. They should not exceed 400 words and should be typed double-spaced.
Autologous blood transfusion
Sir, In the editorial on this subject (May JRSM, p 266)Dr Parker-Williams discusses the fate of blood collected for autologous transfusion but not required by the donating patient. He examines the possibility that this blood could be available for other patients and proposes that regional transfusion centres could be involved in undertaking necessary testing.
A Working Party of the Regional Transfusion Directors' Committee has examined this possibility as part of the preparation of Guidelines for Autologous Transfusion. It was recognized that many patients being considered for autologous transfusion would not fully satisfy the criteria for blood donation as NBTS blood donors. Because of this and because of the logistic problems envisaged in testing and labelling donations which were collected and stored outside by the Regional Transfusion Centre, it was agreed that blood not required by the donating patient could not be offered to other patients. If appropriate tests for HBsAg and HIV on the donation were negative, such blood could be used for laboratory purposes, otherwise unused blood should be discarded. D LEE Chairman, RTD Working Party on Guidelines for Autologous Transfusion, Lancaster
Sir, DrJ Parker-Williams' enthusiasm for autologous blood support services (May JRSM, p 266)is, I'm sure, shared in principle by many of the haematologists who would be called upon to provide these services. Encouragement for the use of autologous blood is to be found in the draft report of the Working Party set up by the Regional Directors' Committee of the National Blood Transfusion Service", whose recommendations aim to ensure the same high level of safety demanded of homologous blood transfusion practice. Most haematologists are, however, reluctant to provide autologous blood facilities because they have neither the staff nor the funds to support a properly organized service. It should come as no surprise that realistic attempts to cost the exercise in established practices have often found it to be similar to the provision of donor blood": it is a labour-intensive procedure which demands its own distinctive documentation, storage facilities and administrative protocol. Many doctors, in their enthusiasm to undertake eminently worthwhile projects, are apt to underestimate the cost of their activities which might otherwise be considered prohibitive. It is a matter of great concern that the paper from St Thomas' Hospital' should draw such an improbable contrast between the costs of donor and autologous blood. On a point of fact, I know of no manufacturer who supplies a blood collection pack for as little as £1. Moreover, I know of no orthopaedic surgeon who equates the cost of a total hip replacement with that of the prosthesis.
